A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.
GPRC5D-Targeted Therapy Continues to be Effective After Dose Reduction in R/R Multiple Myeloma
At a live virtual event, Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma.
Read More
Advancing Myeloma Treatment With Blood-Based MRD Testing
In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Listen
The Myeloma Trial Result I Did Not See Coming
A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.
FDA’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials
The Oncologic Drugs Advisory Committee determined that minimal residual disease could serve as an accelerated approval end point in multiple myeloma clinical trials.
Targeting Multiple Myeloma With the Latest Therapies
In an interview with Targeted Oncology, Adam D. Cohen, MD, discussed the impressive efficacy of FDA-approved agents, alongside their toxicity profiles, for the treatment of multiple myeloma.
FDA Approves Cilta-Cel for Earlier Lines of R/R Multiple Myeloma
The approval follows a unanimous vote by the FDA’s Oncologic Drugs Advisory Committee where they decided the benefits of cilta-cel outweigh the risks for this patient population.